Rituximab for remission in chronic inflammatory demyelinating polyneuropathy
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CIDP by a specialist using specific criteria.
- You are between 18 and 80 years old.
- You have not been treated for CIDP before, or you are on maintenance therapy (IVIg or SCIg) with significant symptoms between doses or a failed withdrawal attempt.
- You do not have active serious infections, severe heart disease, or certain other health conditions.
- You are willing to give informed consent and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This trial tests an investigational drug called Ripertamab for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition causing weakness and numbness. The goal is to see if the drug can improve symptoms compared to no additional treatment.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
Hear when a new CIDP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.